The all-in-one platform to find and track your stocks and investments
Vorteile entdecken
Statistiken
Ertrag
3.59%
Div. Wachstum / 5 Jahre
5% / Jahr
Kapitalisierung
260 Milliarden
Kurs-Gewinn-Verhältnis
21.96 x
Beta (Volatilität)
0.17
Gewinn je Aktie
14.57
In Bezug auf
ISIN : CH0012032048
Preis
Leistungsvergleich
| Roche Holding AG Participat... | |
|---|---|
| 1 Jahr Rückgabe |
+1 %
|
| Rückkehr nach 5 Jahren |
+10 %
|
Bewertung
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 7.15 | 94 % | 0.67 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 4.16 | 3.56 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividendengeschichte
Dividende ohne Unterbrechung
23 Jahr
Frequenz
1x / Jahr
März
Dividenden in %{Jahr}
März
Laufzeit Jahresbetrag
$11.01
Ex-Dividende
28/03/2025
Finanzen
Jährliches Wachstum
Rentabilität
Die Gesundheit
Nachrichten
ASEAN Point of Care Diagnostics Company Evaluation Report 2025 | Abbott, Roche, and Siemens Healthineers Lead with Leadership in Diagnostics, Personalized Care, and AI-Integrated Medical Technologies
Roche Holding AG's (VTX:ROG) top owners are individual investors with 59% stake, while 33% is held by institutions
Analog Devices’s Q2 Earnings Call: Our Top 5 Analyst Questions
PathAI Expands AISight® Dx Primary Diagnosis Clearance to Support VENTANA DP 200 and DP 600 Slide Scanners Through Predetermined Change Control Plan (PCCP)
Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug
Health Care Roundup: Market Talk
Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
Health Canada Approves Roche's Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
Erstellen Sie ein Portfolio und fügen Sie diese Aktion hinzu
Fügen Sie diese und andere Aktien Ihrem virtuellen Portfolio hinzu und erhalten Sie personalisierte Informationen zu jährlichen Gesamtdividenden und dem Gesamtwert sowie Aufschlüsselung nach Branchen und viele weitere Informationen.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.